StockNews.com Begins Coverage on CytRx (NASDAQ:CYTR)

StockNews.com began coverage on shares of CytRx (NASDAQ:CYTRGet Rating) in a report released on Sunday. The firm set a “hold” rating on the stock.

NASDAQ CYTR opened at $0.14 on Friday. CytRx has a 1-year low of $0.09 and a 1-year high of $4.70. The company has a 50 day moving average price of $0.20.

CytRx Company Profile (Get Rating)

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.

See Also

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.